Drug dis­cov­ery spe­cial­ists at Lig­and take their an­ti­body biz pub­lic via SPAC, aim­ing to build $850M com­pa­ny

When Lig­and Phar­ma­ceu­ti­cals un­veiled plans to spin off its an­ti­body dis­cov­ery unit, Om­niAb, last No­vem­ber, the board of di­rec­tors had yet to ap­prove a spe­cif­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER